[go: up one dir, main page]

WO2008010984A3 - Acridine activation of p53 and uses thereof - Google Patents

Acridine activation of p53 and uses thereof Download PDF

Info

Publication number
WO2008010984A3
WO2008010984A3 PCT/US2007/016122 US2007016122W WO2008010984A3 WO 2008010984 A3 WO2008010984 A3 WO 2008010984A3 US 2007016122 W US2007016122 W US 2007016122W WO 2008010984 A3 WO2008010984 A3 WO 2008010984A3
Authority
WO
WIPO (PCT)
Prior art keywords
acridine
activation
apoptosis
stabilization
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/016122
Other languages
French (fr)
Other versions
WO2008010984A9 (en
WO2008010984A2 (en
Inventor
Wafik S El-Deiry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of WO2008010984A2 publication Critical patent/WO2008010984A2/en
Publication of WO2008010984A9 publication Critical patent/WO2008010984A9/en
Publication of WO2008010984A3 publication Critical patent/WO2008010984A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C07D219/12—Amino-alkylamino radicals attached in position 9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

This invention relates to the stabilization of p53 in cells, thereby inducing eitrher cell cycle arrest or apoptosis or both and the consequence of such stabilization on the treatment of cancer. Specifically, the use of acridine and its derivatives in stabilizing p53 through blockage of its ubiquitation, thereby inducing cell cycle arrest or apoptosis in a cell; and the use of these compounds in the treatment of cancer.
PCT/US2007/016122 2006-07-17 2007-07-16 Acridine activation of p53 and uses thereof Ceased WO2008010984A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83120106P 2006-07-17 2006-07-17
US60/831,201 2006-07-17

Publications (3)

Publication Number Publication Date
WO2008010984A2 WO2008010984A2 (en) 2008-01-24
WO2008010984A9 WO2008010984A9 (en) 2008-03-06
WO2008010984A3 true WO2008010984A3 (en) 2008-08-14

Family

ID=38957302

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016122 Ceased WO2008010984A2 (en) 2006-07-17 2007-07-16 Acridine activation of p53 and uses thereof

Country Status (1)

Country Link
WO (1) WO2008010984A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011046757A2 (en) 2009-10-12 2011-04-21 Rajabrata Sarkar Accelerating thrombus resolution through augmentation of p53 activity
US8901129B2 (en) 2009-12-11 2014-12-02 Genecode As Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
WO2011127406A2 (en) * 2010-04-09 2011-10-13 The Brigham And Women's Hospital, Inc. Acridines as inhibitors of haspin and dyrk kinases
CA2944462A1 (en) 2014-03-31 2015-10-08 MiRx Pharmaceuticals, LLC Novel hdmx inhibitors and their use for cancer treatment
US11976041B1 (en) 2023-10-23 2024-05-07 King Faisal University 9-(5-bromo-2-hydroxyphenyl)-10-[3-(dimethylamino)propyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione as an antimicrobial compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOYD M. ET AL.: "NMR Studies of Configuration and Tautomeric Equilibria in Nitroacridine Antitumor Agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 9, September 1990 (1990-09-01), pages 2656 - 2659 *
WANG W. ET AL.: "Acridine Derivatives Activate p53 and Induce Tumor Cell Death through Bax", CANCER BIOLOGY & THERAPY, vol. 5, no. 8, August 2005 (2005-08-01), pages 893 - 898 *

Also Published As

Publication number Publication date
WO2008010984A9 (en) 2008-03-06
WO2008010984A2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
CL2007002642A1 (en) COMPOUNDS DERIVED FROM 3- (6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL) -BENZAMIDA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
IL188050A (en) Azaindazole derivatives, pharmaceutical compositions containing the same and uses thereof
NO20080622L (en) Disycloalkylurea glucokinase activators
WO2007095638A3 (en) Boron-containing small molecules as anti-inflammatory agents
WO2008127364A3 (en) Antiviral compounds and use thereof
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
WO2008029096A8 (en) P53 activating benzoyl urea and benzoyl thiourea compounds
AP2011005637A0 (en) Carbazole compounds and therapeutic uses of the compounds.
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2008144223A3 (en) Triazolyl aminopyrimidine compounds
WO2008010984A3 (en) Acridine activation of p53 and uses thereof
WO2007081878A3 (en) Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
WO2008148754A3 (en) Macrocycles and their uses
WO2008144222A3 (en) Triazolyl aminopyrimidine compounds
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO2006081337A3 (en) Erastin analogues and their uses for killing cancer cells
IL226362A0 (en) Compounds, and methods for the treatment of cancer
ZA201005396B (en) 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative,use thereof,and medicament containing the derivative
BRPI0821432A2 (en) 15,16-Methylene-17-hydroxy-19-nor-21-carboxylic acid steroid gamma-lactone derivative, its use and medicaments containing the derivative.
WO2009118712A3 (en) Novel dihydroxypyrrolidine derivatives as anti-cancer agents
WO2008097341A3 (en) Antiviral compounds and use thereof
TNSN08034A1 (en) Otological solutions containing lapacho extracts
WO2008008507A3 (en) Methods of treatment of diabetes
HK1113133A (en) Substituted oxindol derivatives, drugs containing said derivatives and the use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836086

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07836086

Country of ref document: EP

Kind code of ref document: A2